Nine patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2041
Next term end
6
Patent families
When these terms end
Each bar runs from grant to computed term end. 2022 to 2044.20272032203720422044
16 pending applications: term is not computable until grant.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Feb 2041 · High confidence
Also notable
Ends Aug 2041 · High confidence
Heterocyclic GLP-1 Agonists
US 11,492,365
Granted 2022. Computed term ends 2041.
Heterocyclic GLP-1 Agonists
US 12,528,781
Granted 2026. Too new for citation comparison; protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 13, 2027The maintenance fee for Heterocyclic GLP-1 Agonists (US 11,897,851) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 2 fees due Sep 12, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Heterocyclic GLP-1 Agonists (2022) | 2 in force | to Oct 2041 |
| Heterocyclic GLP-1 Agonists (2023) | 2 in force | to Aug 2041 |
| Heterocyclic GLP-1 Agonists (2022) | 2 in force | to Feb 2041 |
| Heterocyclic GLP-1 Agonists (2024) | 1 in force | to Feb 2044 |
| Heterocyclic GLP-1 Agonists (2023) | 1 in force | to Oct 2042 |
| Heterocyclic GLP-1 Agonists (2025) | 1 in force | to Apr 2041 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,492,365 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 11,926,643 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 12,552,791 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 11,897,851 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 12,528,781 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 12,221,442 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 11,926,626 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 12,595,264 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence | |
| US 12,291,529 | Heterocyclic GLP-1 Agonists In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 16 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.